Literature DB >> 24474051

Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection.

Yaseen M Arabi, Ahmed A Arifi, Hanan H Balkhy, Hani Najm, Abdulaziz S Aldawood, Alaa Ghabashi, Hassan Hawa, Adel Alothman, Abdulaziz Khaldi, Basel Al Raiy.   

Abstract

BACKGROUND: Since September 2012, 170 confirmed infections with Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported to the World Health Organization, including 72 deaths. Data on critically ill patients with MERS-CoV infection are limited.
OBJECTIVE: To describe the critical illness associated with MERS-CoV.
DESIGN: Case series.
SETTING: 3 intensive care units (ICUs) at 2 tertiary care hospitals in Saudi Arabia. PATIENTS: 12 patients with confirmed or probable MERS-CoV infection. MEASUREMENTS: Presenting symptoms, comorbid conditions, pulmonary and extrapulmonary manifestations, measures of severity of illness and organ failure, ICU course, and outcome are described, as are the results of surveillance of health care workers (HCWs) and patients with potential exposure.
RESULTS: Between December 2012 and August 2013, 114 patients were tested for suspected MERS-CoV; of these, 11 ICU patients (10%) met the definition of confirmed or probable cases. Three of these patients were part of a health care-associated cluster that also included 3 HCWs. One HCW became critically ill and was the 12th patient in this case series. Median Acute Physiology and Chronic Health Evaluation II score was 28 (range, 16 to 36). All 12 patients had underlying comorbid conditions and presented with acute severe hypoxemic respiratory failure. Most patients (92%) had extrapulmonary manifestations, including shock, acute kidney injury, and thrombocytopenia. Five (42%) were alive at day 90. Of the 520 exposed HCWs, only 4 (1%) were positive. LIMITATION: The sample size was small.
CONCLUSION: MERS-CoV causes severe acute hypoxemic respiratory failure and considerable extrapulmonary organ dysfunction and is associated with high mortality. Community-acquired and health care-associated MERS-CoV infection occurs in patients with chronic comorbid conditions. The health care-associated cluster suggests that human-to-human transmission does occur with unprotected exposure. PRIMARY FUNDING SOURCE: None.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24474051     DOI: 10.7326/M13-2486

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  277 in total

1.  Genetic Roadmap for Kidney Involvement of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

Authors:  Yue-Miao Zhang; Hong Zhang
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-23       Impact factor: 8.237

2.  Use of non-invasive ventilation for patients with COVID-19: a cause for concern?

Authors:  Nishkantha Arulkumaran; David Brealey; David Howell; Mervyn Singer
Journal:  Lancet Respir Med       Date:  2020-04-21       Impact factor: 30.700

3.  Underlying trend, seasonality, prediction, forecasting and the contribution of risk factors: an analysis of globally reported cases of Middle East Respiratory Syndrome Coronavirus.

Authors:  Omar B Da'ar; Anwar E Ahmed
Journal:  Epidemiol Infect       Date:  2018-06-11       Impact factor: 2.451

4.  Global Health-related Training Opportunities. A National Survey of Pulmonary and Critical Care Medicine Fellowship Programs.

Authors:  Crystal M North; Engi F Attia; Kristina E Rudd; Trishul Siddharthan; Alfred Papali; Başak Çoruh; E Jane Carter; David C Christiani; Jeremy B Richards; Laurence Huang; Ruth Engelberg; William Checkley; T Eoin West
Journal:  Ann Am Thorac Soc       Date:  2019-09

Review 5.  Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models.

Authors:  Yanqun Wang; Jing Sun; Airu Zhu; Jingxian Zhao; Jincun Zhao
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 6.  Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.

Authors:  Jasper F W Chan; Susanna K P Lau; Kelvin K W To; Vincent C C Cheng; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 7.  MERS coronavirus: diagnostics, epidemiology and transmission.

Authors:  Ian M Mackay; Katherine E Arden
Journal:  Virol J       Date:  2015-12-22       Impact factor: 4.099

Review 8.  Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.

Authors:  Arjen M Dondorp; Muhammad Hayat; Diptesh Aryal; Abi Beane; Marcus J Schultz
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

Review 9.  Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus.

Authors:  Anthony R Fehr; Rudragouda Channappanavar; Stanley Perlman
Journal:  Annu Rev Med       Date:  2016-08-26       Impact factor: 13.739

Review 10.  Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.